Migraine diagnosis and treatment in Poland: survey of primary care practitioners
Abstract
Aim of the study: This study aimed to analyze the daily clinical practice of primary care practitioners (PCPs) in Poland concerning migraine patients.
Clinical rationale for the study: Migraine is a common chronic primary headache disease, which can be disabling if insufficiently managed. Numerous studies suggest that migraine remains underdiagnosed and undertreated. The first consultation of migraine patients is usually undertaken by a PCP.
Materials and methods: This study was conducted in June and July 2019 in Poland using a computer-assisted web interview with 51 PCPs. The interview questions concerned knowledge of diagnostic criteria and methods of migraine treatment.
Results: On average, each PCP consulted 12 patients with migraine per month. More than half of PCPs (63%) listed partial diagnostic criteria for migraine without aura or mentioned aura in their responses. Only 10% of PCPs listed all diagnostic criteria for migraine without aura. Although 55% of PCPs said that they distinguished between episodic and chronic migraine, 18% provided the wrong definition. The most commonly prescribed drugs were triptans (66%), paracetamol, metamizole, or non-steroidal anti-inflammatory drugs (42%).
Conclusions and clinical implications: PCPs play a critical role in diagnosing, treating, and monitoring migraine; however, many of them have insufficient knowledge about its diagnosis and correct differentiation between chronic and episodic forms.
Keywords: chronic migraineepisodic migraineheadacheprimary care practitioner
References
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002; 346(4): 257–270.
- Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010; 30(5): 599–609.
- Karbowniczek A, Domitrz I. Frequency and clinical characteristics of chronic daily headache in an outpatient clinic setting. Neurologia i Neurochirurgia Polska. 2011; 45(1): 11–17.
- Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain. 2005; 6(6): 429–440.
- Linde M, Dahlöf C. Attitudes and burden of disease among self-considered migraineurs--a nation-wide population-based survey in Sweden. Cephalalgia. 2004; 24(6): 455–465.
- Radtke A, Neuhauser H. Low rate of self-awareness and medical recognition of migraine in Germany. Cephalalgia. 2012; 32(14): 1023–1030.
- World Health Organization, Lifting The Burden Atlas of headache disorders and resources in the world 2011. Geneva. 2011.
- Domitrz I, Lipa A, Rożniecki J, et al. Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies. Neurol Neurochir Pol. 2020; 54(4): 337–343.
- Domitrz I, Lipa A, Rozniecki J, et al. Polish omnibus online survey on migraine conducted in a population of 2000 adults. Migrena news . 2019; 3(6): 98–100.
- Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006; 77(3): 385–387.
- Lantéri-Minet M. The role of general practitioners in migraine management. Cephalalgia. 2008; 28 Suppl 2: 1–8.
- Becker WJ. The diagnosis and management of chronic migraine in primary care. Headache. 2017; 57(9): 1471–1481.
- Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016; 128(5): 523–537.
- Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018; 19(1): 10.
- Health Data Management database, FarmaProm Polska. . https://www.farmaprom.pl/en/database (01.06.2019).
- Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011; 51(7): 1058–1077.
- Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003; 60(3): 441–448.
- Gültekin M, Balci E, İsmailoğullari S, et al. Awareness of migraine among primary care physicians in Turkey: A regional study. Noro Psikiyatr Ars. 2018; 55(4): 354–357.
- Bösner S, Hartel S, Diederich J, et al. Diagnosing headache in primary care: a qualitative study of GPs' approaches. Br J Gen Pract. 2014; 64(626): e532–e537.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629–808.
- Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008; 48(8): 1157–1168.
- May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016; 12(8): 455–464.
- Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71(8): 559–566.
- Aguirrezabal I, Pérez de San Román MS, Cobos-Campos R, et al. Effectiveness of a primary care-based group educational intervention in the management of patients with migraine: a randomized controlled trial. Prim Health Care Res Dev. 2019; 20: e155.
- Becker WJ. Acute migraine treatment in adults. Headache. 2015; 55(6): 778–793.
- Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013; 53(3): 427–436.
- Dodick D. Migraine. The Lancet. 2018; 391(10127): 1315–1330.
- Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016; 128(5): 523–537.
- Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78(17): 1337–1345.
- Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019; 20(1): 6.
- Społeczne znaczenie migreny z perspektywy zdrowia publicznego i systemu ochrony zdrowia. Zakład Analiz Ekonomicznych i Systemowych Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny. 2019. https://www.pzh.gov.pl/wp-content/uploads/2019/06/RAPORT-MIGRENA-ca%C5%82y.pdf.
